Evidence map›Paper›PMID 26720415›Full record

ArticlePLoS pathogens2015

Live Cell Analysis and Mathematical Modeling Identify Determinants of Attenuation of Dengue Virus 2'-O-Methylation Mutant.

Bianca Schmid, Melanie Rinas, Alessia Ruggieri, Eliana Gisela Acosta, Marie Bartenschlager, Antje Reuter, Wolfgang Fischl, Nathalie Harder, Jan-Philip Bergeest, Michael Flossdorf and 3 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
6.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 58 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Stochastic dynamics of Type-I interferon responses.PLoS computational biology · 2022
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Bianca SchmidDepartment of Infectious Diseases, Molecular Virology, University of Heidelberg, Heidelberg, Germany.
Melanie RinasDivision of Theoretical Systems Biology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Alessia RuggieriDepartment of Infectious Diseases, Molecular Virology, University of Heidelberg, Heidelberg, Germany.
Eliana Gisela AcostaDepartment of Infectious Diseases, Molecular Virology, University of Heidelberg, Heidelberg, Germany.
Marie BartenschlagerDepartment of Infectious Diseases, Molecular Virology, University of Heidelberg, Heidelberg, Germany.
Antje ReuterDepartment of Infectious Diseases, Molecular Virology, University of Heidelberg, Heidelberg, Germany.
Wolfgang FischlDepartment of Infectious Diseases, Molecular Virology, University of Heidelberg, Heidelberg, Germany.
Nathalie HarderBioQuant Center, University of Heidelberg, Heidelberg, Germany.
Jan-Philip BergeestBioQuant Center, University of Heidelberg, Heidelberg, Germany.
Michael FlossdorfDivision of Theoretical Systems Biology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Karl RohrBioQuant Center, University of Heidelberg, Heidelberg, Germany.
Thomas HöferDivision of Theoretical Systems Biology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Ralf BartenschlagerDepartment of Infectious Diseases, Molecular Virology, University of Heidelberg, Heidelberg, Germany.
Heidelberg University · DEGerman Cancer Research Center · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dengue virus (DENV) is the most common mosquito-transmitted virus infecting ~390 million people worldwide. In spite of this high medical relevance, neither a vaccine nor antiviral therapy is currently available. DENV elicits a strong interferon (IFN) response in infected cells, but at the same time actively counteracts IFN production and signaling. Although the kinetics of activation of this innate antiviral defense and the timing of viral counteraction critically determine the magnitude of infection and thus disease, quantitative and kinetic analyses are lacking and it remains poorly understood how DENV spreads in IFN-competent cell systems. To dissect the dynamics of replication versus antiviral defense at the single cell level, we generated a fully viable reporter DENV and host cells with authentic reporters for IFN-stimulated antiviral genes. We find that IFN controls DENV infection in a kinetically determined manner that at the single cell level is highly heterogeneous and stochastic. Even at high-dose, IFN does not fully protect all cells in the culture and, therefore, viral spread occurs even in the face of antiviral protection of naïve cells by IFN. By contrast, a vaccine candidate DENV mutant, which lacks 2'-O-methylation of viral RNA is profoundly attenuated in IFN-competent cells. Through mathematical modeling of time-resolved data and validation experiments we show that the primary determinant for attenuation is the accelerated kinetics of IFN production. This rapid induction triggered by mutant DENV precedes establishment of IFN-resistance in infected cells, thus causing a massive reduction of virus production rate. In contrast, accelerated protection of naïve cells by paracrine IFN action has negligible impact. In conclusion, these results show that attenuation of the 2'-O-methylation DENV mutant is primarily determined by kinetics of autocrine IFN action on infected cells.

Indexed as

Models, TheoreticalCell LineCell SurvivalDengueDengue VaccinesDengue VirusEnzyme-Linked Immunosorbent AssayFlow CytometryFluorescent Antibody TechniqueHumansImmunoblottingInterferonsMethylationReal-Time Polymerase Chain ReactionRNA, ViralDengue VaccinesInterferonsRNA, Viral

Identifiers

PMID26720415
PMCPMC4697809
OpenAlexW2220853306

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.